Physician profile
Trevor D Smith
NPI 1285166314
$1,100.56
in general payments reported to CMS, 2019-2025
20 companies · $520 in 2025
The $520 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.19 · 2023: $331 · 2024: $204 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $398.23 | 2023-2025 | Azstarys |
| Pfizer INC. | $73.12 | 2024-2025 | |
| Glaxosmithkline, LLC. | $72.09 | 2022-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $57.69 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $57.06 | 2023 | M-M-R II, Gardasil 9, Vaxelis |
| Cranial Technologies, INC | $45.36 | 2024-2025 | Doc Band |
| Tris Pharma INC | $43.22 | 2024-2025 | Dyanavel Xr |
| Alk-Abello, INC | $39.96 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $34.78 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $34.18 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $33.64 | 2025 | Voxzogo 1.2mg |
| Astrazeneca Pharmaceuticals LP | $32.30 | 2023 | Flumist Quadrivalent |
| Cumberland Pharmaceuticals, INC. | $31.18 | 2022-2024 | Kristalose |
| Lnhc, INC | $30.74 | 2025 | Zelsuvmi |
| Ultragenyx Pharmaceutical INC. | $28.85 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21.69 | 2025 | Qelbree |
| Biomerieux INC | $20.98 | 2023 | |
| Acadia Pharmaceuticals INC | $16.61 | 2025 | Daybue |
| Cipher Pharmaceuticals US LLC | $15.45 | 2025 | Spinosad, Natroba |
| Seqirus USA INC | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.